Microbial Tryptamine as a Causative Cofactor of Incurable Cell Death Diseases of Unknown Etiology
The Cost of Related Healthcare in the US and Worldwide
- 1st Edition - April 1, 2026
- Latest edition
- Author: Elena L. Paley
- Language: English
Microbial Tryptamine as a Causative Cofactor of Incurable Cell Death Diseases of Unknown Etiology: The Cost of Related Healthcare in the US and Worldwide explores the pivota… Read more
Purchase options
Microbial Tryptamine as a Causative Cofactor of Incurable Cell Death Diseases of Unknown Etiology: The Cost of Related Healthcare in the US and Worldwide explores the pivotal role of microbial tryptamine in the onset and progression of diseases such as Alzheimer’s and Parkinson’s. The book investigates how tryptamine contributes to neurodegeneration, various cancers, and gastrointestinal disorders, emphasizing how environmental and dietary factors may influence disease development. It also addresses the implications of tryptamine for cell and organ transplantation, while offering an in-depth look at the latest advances in treatment and prevention for these incurable illnesses.
Beyond biological mechanisms, the book critically examines the economic impact of tryptamine-related diseases on healthcare systems worldwide, providing detailed analyses of current spending, market trends, and funding structures. It highlights challenges in biomedical research—including competition, plagiarism, and article retractions—and underscores the importance of collaboration between researchers and clinicians.
Beyond biological mechanisms, the book critically examines the economic impact of tryptamine-related diseases on healthcare systems worldwide, providing detailed analyses of current spending, market trends, and funding structures. It highlights challenges in biomedical research—including competition, plagiarism, and article retractions—and underscores the importance of collaboration between researchers and clinicians.
- Explores microbial tryptamine in diseases like cancer, Alzheimer's disease, and Parkinson’s disease, and its effects on the gut microbiome
- Analyzes research funding related to tryptamine-induced diseases of unknown etiology, advocating for the need to invest in further treatment and laboratory diagnostic tests
- Addresses systemic issues in biomedical research and the need to improve scientific integrity
- Explores healthcare expenditures linked to tryptamine-associated pathologies
Researchers in biology, biomedicine, biochemistry, molecular biology working with microbial tryptamine and its impact on human health and disease
Part 1. Microbial tryptamine in diseases
1. Introduction: Contamination of food products with microbes producing cytotoxic tryptamine that induces gut dysbiosis
2. Differential abundance of tryptamine and related human gut microbial NQR sequence (ADAS) in cancers of gastrointestinal (GI) system and neurodegenerative diseases, spending budgets
3. Tryptamine in cell and organ transplantation
4. The roles of the diet and environment in the start and progression of diseases
5. Tryptamine-induced diseases: Future of biomedicine in saving lives by testing, preventing and treating the preventable/avoidable and modifiable medical conditions
Part 2. Expenditure and research funding
6. Expenditure on diseases related to tryptamine-induced cell toxicity and neurodegeneration
7. Funding of research projects and market analysis for diseases related to tryptamine
Part 3. Research-related issues interfering with the progress in the biomedical project
8. Competition, plagiarism and profit-driven motives in science
9. Massive retractions of funded articles is a symptom of serious failures in research funding
10. How do biology doctors and medical doctors - clinicians collaborate?
Part 4. A personal narrative and conclusive remarks
11. About the Author
12. Conclusions
1. Introduction: Contamination of food products with microbes producing cytotoxic tryptamine that induces gut dysbiosis
2. Differential abundance of tryptamine and related human gut microbial NQR sequence (ADAS) in cancers of gastrointestinal (GI) system and neurodegenerative diseases, spending budgets
3. Tryptamine in cell and organ transplantation
4. The roles of the diet and environment in the start and progression of diseases
5. Tryptamine-induced diseases: Future of biomedicine in saving lives by testing, preventing and treating the preventable/avoidable and modifiable medical conditions
Part 2. Expenditure and research funding
6. Expenditure on diseases related to tryptamine-induced cell toxicity and neurodegeneration
7. Funding of research projects and market analysis for diseases related to tryptamine
Part 3. Research-related issues interfering with the progress in the biomedical project
8. Competition, plagiarism and profit-driven motives in science
9. Massive retractions of funded articles is a symptom of serious failures in research funding
10. How do biology doctors and medical doctors - clinicians collaborate?
Part 4. A personal narrative and conclusive remarks
11. About the Author
12. Conclusions
- Edition: 1
- Latest edition
- Published: April 1, 2026
- Language: English
EP
Elena L. Paley
Dr. Paley is Cofounder of the nonprofit Stop Alzheimers Corp and Founder of Expert Biomed, Inc. She holds a PhD degree in biology with specialization in molecular biology from the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences in the Laboratory of Lev L. Kisselev. Dr. Paley’s research focuses mainly on protein biosynthesis in biology and diseases and is conducted in collaboration with Harvard University, Brandeis University, the University of Miami, Tel Aviv University, the Institut des Vaisseaux et du Sang (Paris, France), and the University of Texas at San Antonio. She is Adjunct Professor at Nova Southeastern University, FL, United States, and is inventor in patents issued and pending. Dr. Paley has previously published 4 books with Elsevier.
Affiliations and expertise
Adjunct Professor at Nova Southeastern University, FL,, USA